Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Genoss has commercialized multiple medical device products globally. Its Monalisa hyaluronic acid filler line has demonstrated safety and efficacy in aesthetic indications with at least one multicenter clinical study comparing it to leading competitors. The company’s sirolimus-eluting coronary stent system ("GENOSS DES") and OSFIT Drug-Eluting Stent are currently being evaluated in prospective multicenter clinical trials targeting patients with multivessel coronary artery disease or ostial lesions. The company also markets FDA/CE-approved orthopedic implants and dental materials.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Genoss.